Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Authors
Georg Heß (ORCID: https://orcid.org/0000-0002-9282-5688)
Eva Cybulski
Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
Norma Carmen Gutierrez (ORCID: https://orcid.org/0000-0001-5834-9510)
Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Georg Heß, Eva Cybulski, Laurie H. Sehn, Norma Carmen Gutierrez et al.
Journal
Blood
Topics
CAR-T cell therapy research
article
Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Georg Heß, Eva Cybulski, Laurie H. Sehn, Norma Carmen Gutierrez, Martin Dreyling, Denison Kuruvilla, Michael C. Wei, Sarit Assouline, Samuel Tracy, Nancy L. Bartlett, Stephen J. Schuster, Lihua E. Budde, Volker Wiebking, John Kuruvilla, Joseph Chen, Sung‐Soo Yoon, Pratyush Giri, Keith Fay, Fidelis Sabalvaro, Elicia Peneul
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
City Of Hope National Medical Center (US), Royal Adelaide Hospital (AU), University of British Columbia (CA), Universidad de Salamanca (ES), Johannes Gutenberg University Mainz (DE), Washington University in St. Louis (US), Royal North Shore Hospital (AU), Jewish General Hospital (CA), Spinal Cord Injury BC (CA), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), LMU Klinikum (DE), St Vincent's Hospital Melbourne (AU), University Medical Center of the Johannes Gutenberg University Mainz (DE), Acentech (United States) (US), Temple University Health System (US), Instituto de Investigación Biomédica de Salamanca (ES), Ludwig-Maximilians-Universität München (DE)